Difference between revisions of "Erlotinib (Tarceva)"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m
Line 24: Line 24:
  
 
==History of changes in FDA indication==
 
==History of changes in FDA indication==
−
*11/18/2004: [http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm209058.htm Approved] for treatment of locally advanced or metastatic [[Non-small cell lung cancer | NSCLC]] after failure of at least one prior chemotherapy regimen.<ref name="insert"></ref>
+
===[[Non-small cell lung cancer]]===
−
*11/2/2005: Approved as first-line treatment of patients with locally advanced, unresectable or metastatic [[Pancreatic cancer | pancreatic cancer]], in combination with [[Gemcitabine (Gemzar) | gemcitabine]].<ref name="insert"></ref>
+
*11/18/2004: [http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm209058.htm Approved] for treatment of locally advanced or metastatic [[Non-small cell lung cancer | NSCLC]] after failure of at least one prior chemotherapy regimen. ''(Based on NCIC-CTG BR.21)''
−
*4/16/2010: [http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm209058.htm Approved] for maintenance treatment of patients with locally advanced or metastatic [[Non-small cell lung cancer | non-small cell lung cancer (NSCLC)]] whose disease has not progressed after four cycles of [[Regimen_classes#Platinum-based_regimen | platinum-based]] first-line chemotherapy.<ref name="insert"></ref>
+
*4/16/2010: [http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm209058.htm Approved] for maintenance treatment of patients with locally advanced or metastatic [[Non-small cell lung cancer | non-small cell lung cancer (NSCLC)]] whose disease has not progressed after four cycles of [[Regimen_classes#Platinum-based_regimen | platinum-based]] first-line chemotherapy. ''(Based on SATURN)''
−
*5/14/2013: [http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm352230.htm Approved] for first-line treatment of patients with metastatic [[Non-small cell lung cancer | non-small cell lung cancer (NSCLC)]] whose tumors have [[Biomarkers#EGFR|epidermal growth factor receptor (EGFR)]] [[Biomarkers#Exon_19|exon 19]] [[#Biomarkers_Structural Variant|deletion]] or [[Biomarkers#L858R|exon 21 (L858R) substitution]] mutations as detected by an FDA-approved test.<ref name="insert"></ref>
+
*5/14/2013: [http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm352230.htm Approved] for first-line treatment of patients with metastatic [[Non-small cell lung cancer | non-small cell lung cancer (NSCLC)]] whose tumors have [[Biomarkers#EGFR|epidermal growth factor receptor (EGFR)]] [[Biomarkers#Exon_19|exon 19]] [[Biomarkers#Deletion|deletion]] or [[Biomarkers#L858R|exon 21 (L858R) substitution]] mutations as detected by an FDA-approved test. ''(Based on EURTAC)''
−
*10/18/2016: [http://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm525739.htm Label revised] to limit use to those patients whose tumors have [[Biomarkers#EGFR|EGFR]] [[Biomarkers#Exon_19|exon 19]] [[#Biomarkers_Structural Variant|deletions]] or [[Biomarkers#L858R|exon 21 L858R substitution]] mutations as detected by an FDA-approved test. This limitation pertains to patients with [[Non-small cell lung cancer |NSCLC]] receiving maintenance or second or greater line treatment.
+
*10/18/2016: [http://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm525739.htm Label revised] to limit use to those patients whose tumors have [[Biomarkers#EGFR|EGFR]] [[Biomarkers#Exon_19|exon 19]] [[Biomarkers#Deletion|deletions]] or [[Biomarkers#L858R|exon 21 L858R substitution]] mutations as detected by an FDA-approved test. This limitation pertains to patients with [[Non-small cell lung cancer |NSCLC]] receiving maintenance or second or greater line treatment. ''(Based on IUNO)''
 +
 
 +
===[[Pancreatic cancer]]===
 +
*11/2/2005: Approved as first-line treatment of patients with locally advanced, unresectable or metastatic [[pancreatic cancer]], in combination with [[Gemcitabine (Gemzar) | gemcitabine]]. ''(Based on NCIC-CTG PA.3)''
  
 
==Also known as==
 
==Also known as==

Revision as of 20:53, 11 May 2021

General information

Class/mechanism: Small molecule tyrosine kinase inhibitor. Inhibits the intracellular phosphorylation activity of the epidermal growth factor receptor (EGFR) tyrosine kinase; may also have activity against other tyrosine kinase receptors. Exact mechanism of antitumor action is not fully characterized.[1][2][3]
Route: PO
Extravasation: n/a

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]

Diseases for which it is used

Patient drug information

History of changes in FDA indication

Non-small cell lung cancer

Pancreatic cancer

  • 11/2/2005: Approved as first-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer, in combination with gemcitabine. (Based on NCIC-CTG PA.3)

Also known as

  • Code names: CP-358, CP-774, OSI-774
  • Generic name: erlotinib hydrochloride
  • Brand names: Erlocip, Erlonat, Melacyte, Tarceva

References

  1. ↑ 1.0 1.1 1.2 Erlotinib (Tarceva) package insert
  2. ↑ Erlotinib (Tarceva) package insert (locally hosted backup)
  3. ↑ Tarceva manufacturer's website
  4. ↑ Erlotinib (Tarceva) patient drug information (Chemocare)
  5. ↑ Erlotinib (Tarceva) patient drug information (UpToDate)
Retrieved from "https://hemonc.org/w/index.php?title=Erlotinib_(Tarceva)&oldid=49582"